Work

Vasopressin, steroids, and epinephrine in out-of-hospital cardiac arrest – a protocol for a randomized controlled trial (OHCA REVIVES trial)

Year: 2025

Type: article

Abstract: Objective: Several clinical trials have shown promising results for the vasopressin-steroid-epinephrine (VSE) triple therapy in patients experiencing in-hospital cardiac arrest (IHCA); however, this treatment strategy has not yet been studied in the prehospital setting. The OHCA REVIVES (A Randomized Clinical Trial of Patient Outcomes Following Out-of-Hospital Cardiac Arrest Receiving Epinephrine Versus In-together Vasopressin, Epinephrine, and Steroid) trial aims to evaluate the effectiveness of the VSE combined therapy in improving clinical outcomes in patients with out‑of‑hospital cardiac arrest (OHCA). Methods: The OHCA REVIVES trial is an investigator-initiated, multicenter, superiority cluster randomized controlled trial. Adult non-traumatic patients with OHCA treated by six participating advanced ambulance teams in Taipei and New Taipei City, Taiwan will be included. Biweekly randomized clusters of participating advanced ambulance teams were assigned to administer either VSE combined therapy or standard care during cardiac arrest. The primary outcome is sustained return of spontaneous circulation (ROSC ≥ 2 h), and key secondary outcomes include prehospital ROSC, survival to hospital discharge, and survival with favorable neurologic outcomes (cerebral performance category score ≤ 2) at hospital discharge. A total of 1344 patients will be included. Conclusion: ClinicalTrials.gov (identifier: NCT06203847; date registered: January 12, 2024).

Source: Resuscitation Plus

DOI: 10.1016/j.resplu.2025.101163